Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.

中文翻译：

---

在 B 细胞耗尽的多发性硬化症患者中从 COVID-19 中恢复

全球约有 200,000 名多发性硬化症 (MS) 患者接受利妥昔单抗（抗 CD20）的 B 细胞耗竭免疫疗法，这消除了对新感染产生抗体反应的能力。由于严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 特异性抗体可能有助于清除病毒，因此这些患者如果被感染可能会面临严重并发症的风险。在这里，我们报告了一位接受利妥昔单抗约 3 年的 MS 患者。该患者在 2019 年冠状病毒病 (COVID-19) 症状出现前 5 天接受了检查，并在 2 天后入院。尽管 B 淋巴细胞计数为 0% 且未出现 SARS-CoV-2 免疫球蛋白 G (IgG) 抗体，但她在症状出现 14 天后康复。